title: [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
abstract: Twenty-four previously untreated patients with a diagnosis of prostatic cancer were treated with chlormadinone acetate (CMA) alone (100 mg/day) for 4 weeks, and luteinizing hormone-releasing hormone analogue (LH-RHa) was added for the next 24 weeks. Marked decreases in blood LH, testosterone (T), prostate specific antigen (PSA), gamma-seminoprotein (gamma-Sm), and prostatic acid phosphatase (PAP) were observed after a single dose of CMA. T levels were significantly increased 3 days after the initial dose of LH-RHa, and did not return to the pretreatment level. There were no significant increases in any of the markers, nor were there any flare-up cases. Triglyceride levels, which were slightly elevated before the start of treatment, were significantly decreased 24 weeks after the completion of combined therapy. PSA was evaluated as partial response (PR) or better in 86.7% of the patients. Overall evaluation showed PR or better in 75.0% of the patients. These findings suggest that prior administration of CMA followed by combined administration with LH-RHa is useful in the treatment of prostatic cancer. No negative effects on lipid metabolism were observed at any time during the treatment period.
authors.affiliation: Department of Urology, Showa University, School of Medicine.
authors.forename: M
authors.initials: M
authors.lastname: Shimada
authors.forename: H
authors.initials: H
authors.lastname: Uchida
authors.forename: T
authors.initials: T
authors.lastname: Kasahara
authors.forename: K
authors.initials: K
authors.lastname: Fuji
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: T
authors.initials: T
authors.lastname: Hamajima
authors.forename: N
authors.initials: N
authors.lastname: Matsuda
authors.forename: T
authors.initials: T
authors.lastname: Ikeuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kai
authors.forename: M
authors.initials: M
authors.lastname: Hiramori
authors.forename: M
authors.initials: M
authors.lastname: Hoshino
authors.forename: K
authors.initials: K
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Higaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001053:Apolipoproteins / Q000097:blood; D002715:Chlormadinone Acetate / Q000008:administration & dosage*; D002784:Cholesterol / Q000097:blood; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D045167:Progesterone Congeners / Q000008:administration & dosage*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood
chemical_list: D018931:Antineoplastic Agents, Hormonal; D001053:Apolipoproteins; D045167:Progesterone Congeners; D014280:Triglycerides; D002715:Chlormadinone Acetate; D013739:Testosterone; D002784:Cholesterol; D017430:Prostate-Specific Antigen; D016729:Leuprolide